<?xml version="1.0" encoding="UTF-8"?><rss version="2.0" xmlns:content="http://purl.org/rss/1.0/modules/content/"><channel><title>医药笔记 | wechat-feeds</title><link>http://MzI4MzQyMjM0Ng.favicon.privacyhide.com/favicon.ico</link><description>乘之愈往，识之愈真。如将不尽，与古为新。</description><managingEditor> (hellodword)</managingEditor><pubDate>Wed, 03 Feb 2021 11:44:10 +0800</pubDate><image><url>http://MzI4MzQyMjM0Ng.favicon.privacyhide.com/favicon.ico</url><title>医药笔记 | wechat-feeds</title><link>http://MzI4MzQyMjM0Ng.favicon.privacyhide.com/favicon.ico</link><width>64</width><height>64</height></image><item><title>HanAll FcRn抗体因血脂升高副作用停止TED、WAHA临床，和铂医药未进行相关适应症临床，亦未发现血脂副作用</title><link>https://mp.weixin.qq.com/s/7zuiM2M3IUMs_u8VJKkKsQ</link><description></description><content:encoded><![CDATA[HanAll FcRn抗体因血脂升高副作用停止TED、WAHA临床，和铂医药未进行相关适应症临床，亦未发现血脂副作用]]></content:encoded><pubDate>Wed, 03 Feb 2021 09:56:28 +0800</pubDate></item><item><title>安进DLL3-CD3双抗在实体瘤中取得重大突破</title><link>https://mp.weixin.qq.com/s/ndWhDjCLt8WjR9iJGrESRQ</link><description></description><content:encoded><![CDATA[安进DLL3-CD3双抗在实体瘤中取得重大突破]]></content:encoded><pubDate>Wed, 03 Feb 2021 09:56:28 +0800</pubDate></item><item><title>诺诚健华增发筹资30.45亿港元，高瓴资本认购26.7亿</title><link>https://mp.weixin.qq.com/s/z8B10CAFZxAB0kSjmFLIdQ</link><description></description><content:encoded><![CDATA[诺诚健华增发筹资30.45亿港元，高瓴资本认购26.7亿]]></content:encoded><pubDate>Wed, 03 Feb 2021 09:56:28 +0800</pubDate></item><item><title>地平线30亿美元收购Viela，豪森拥有其CD19抗体中国权益</title><link>https://mp.weixin.qq.com/s/l95fuqgTq2Fhm0reCuVZoQ</link><description></description><content:encoded><![CDATA[地平线30亿美元收购Viela，豪森拥有其CD19抗体中国权益]]></content:encoded><pubDate>Tue, 02 Feb 2021 09:31:51 +0800</pubDate></item><item><title>百亿剂新冠疫苗</title><link>https://mp.weixin.qq.com/s/Ida2cfICmSjuHWujtneO-w</link><description></description><content:encoded><![CDATA[百亿剂新冠疫苗]]></content:encoded><pubDate>Mon, 01 Feb 2021 12:47:06 +0800</pubDate></item><item><title>胰岛素百年传奇</title><link>https://mp.weixin.qq.com/s/dD-fngfSSoFAB2hPsFtuGA</link><description></description><content:encoded><![CDATA[胰岛素百年传奇]]></content:encoded><pubDate>Sun, 31 Jan 2021 14:55:26 +0800</pubDate></item><item><title>安进申报BLyS/ICOS双抗：AMG 570</title><link>https://mp.weixin.qq.com/s/piEhK3hfOcPqDeom_947lA</link><description></description><content:encoded><![CDATA[安进申报BLyS/ICOS双抗：AMG 570]]></content:encoded><pubDate>Sat, 30 Jan 2021 09:10:04 +0800</pubDate></item><item><title>强生新冠疫苗有效率66%，仅需一次注射</title><link>https://mp.weixin.qq.com/s/t6gEtk-wVy15PtqphGSiHw</link><description></description><content:encoded><![CDATA[强生新冠疫苗有效率66%，仅需一次注射]]></content:encoded><pubDate>Sat, 30 Jan 2021 09:10:04 +0800</pubDate></item><item><title>新冠中和抗体2020年销售额：礼来8.71亿美元，再生元1.84亿美元</title><link>https://mp.weixin.qq.com/s/s9cfx741rMoq3oBDoSnBFw</link><description></description><content:encoded><![CDATA[新冠中和抗体2020年销售额：礼来8.71亿美元，再生元1.84亿美元]]></content:encoded><pubDate>Sat, 30 Jan 2021 09:10:04 +0800</pubDate></item><item><title>肿瘤免疫版ADC</title><link>https://mp.weixin.qq.com/s/OPTS-AbAbn4la0767mBGkQ</link><description></description><content:encoded><![CDATA[肿瘤免疫版ADC]]></content:encoded><pubDate>Fri, 29 Jan 2021 07:57:49 +0800</pubDate></item><item><title>恒瑞医药研发PD-L1/4-1BB双抗</title><link>https://mp.weixin.qq.com/s/h_I20S8CPcwE9rUe8HzB8g</link><description></description><content:encoded><![CDATA[恒瑞医药研发PD-L1/4-1BB双抗]]></content:encoded><pubDate>Fri, 29 Jan 2021 07:57:49 +0800</pubDate></item><item><title>金斯瑞研发CD47/LAG-3双抗</title><link>https://mp.weixin.qq.com/s/FO8QsoKAAFGnea5qok6Ulg</link><description></description><content:encoded><![CDATA[金斯瑞研发CD47/LAG-3双抗]]></content:encoded><pubDate>Fri, 29 Jan 2021 07:57:49 +0800</pubDate></item><item><title>恒瑞医药申报第四款ADC药物：SHR-A1904</title><link>https://mp.weixin.qq.com/s/NqGMGx7OKxCIjfM3QQqzew</link><description></description><content:encoded><![CDATA[恒瑞医药申报第四款ADC药物：SHR-A1904]]></content:encoded><pubDate>Fri, 29 Jan 2021 07:57:49 +0800</pubDate></item><item><title>Novavax新冠疫苗有效率89.3%，对英国和南非变异株同样有效</title><link>https://mp.weixin.qq.com/s/XgA5g5pAWe0BB560c5CJNA</link><description></description><content:encoded><![CDATA[Novavax新冠疫苗有效率89.3%，对英国和南非变异株同样有效]]></content:encoded><pubDate>Fri, 29 Jan 2021 07:57:49 +0800</pubDate></item><item><title>CAR-T升级：OX40新装备</title><link>https://mp.weixin.qq.com/s/AlFpOUEKyjwLy1N1cPOFnw</link><description></description><content:encoded><![CDATA[CAR-T升级：OX40新装备]]></content:encoded><pubDate>Thu, 28 Jan 2021 13:24:50 +0800</pubDate></item><item><title>错过安全性终点：辉瑞JAK抑制剂Tofacitinib</title><link>https://mp.weixin.qq.com/s/JxVR4zbTXMd3wkEoDIlP4Q</link><description></description><content:encoded><![CDATA[错过安全性终点：辉瑞JAK抑制剂Tofacitinib]]></content:encoded><pubDate>Thu, 28 Jan 2021 13:24:50 +0800</pubDate></item><item><title>乙肝中和抗体脱颖而出，Vir Biotechnology股价大涨74%</title><link>https://mp.weixin.qq.com/s/jzJM5kakGkF4f7rTtgIUmg</link><description></description><content:encoded><![CDATA[乙肝中和抗体脱颖而出，Vir Biotechnology股价大涨74%]]></content:encoded><pubDate>Wed, 27 Jan 2021 06:44:08 +0800</pubDate></item><item><title>降低住院和死亡率高达70%：礼来/君实新冠中和抗体鸡尾酒三期临床成功</title><link>https://mp.weixin.qq.com/s/Wev_pQzgbeYt4Wcpv8IqPw</link><description></description><content:encoded><![CDATA[降低住院和死亡率高达70%：礼来/君实新冠中和抗体鸡尾酒三期临床成功]]></content:encoded><pubDate>Wed, 27 Jan 2021 06:44:08 +0800</pubDate></item><item><title>有症状感染保护率100%：再生元中和抗体鸡尾酒用作疫苗</title><link>https://mp.weixin.qq.com/s/r9Hctahk-qXL_O8WDnB_Yg</link><description></description><content:encoded><![CDATA[有症状感染保护率100%：再生元中和抗体鸡尾酒用作疫苗]]></content:encoded><pubDate>Wed, 27 Jan 2021 06:44:08 +0800</pubDate></item><item><title>ERBB受体家族</title><link>https://mp.weixin.qq.com/s/JZfho9O6DQTt87ifaqOCtQ</link><description></description><content:encoded><![CDATA[ERBB受体家族]]></content:encoded><pubDate>Tue, 26 Jan 2021 14:08:04 +0800</pubDate></item></channel></rss>